Sona Nanotech Halts COVID-19 Rapid Saliva Test Trials, Drops Research Program

Sona Nanotech (CSE: SONA) this morning had bombshell news, in that it has discontinued its clinical trial for a COVID-19 rapid antigen saliva test. The announcement follows the news from just two months ago that the company would be working with Humber River Hospital in Toronto to determine the clinical performance of the test.

In its announcement this morning, the company indicated that “encouraging analytical test results did not translate to an ability to consistently detect the virus in clinical samples.” Commenting on this, the clinical trial investigator Dr David Jacobs stated, “While there are many possible reasons for this discrepancy, the favored hypotheses are that either there is insufficient viral concentration in saliva, or there is an interfering substance in the saliva.

In more detail, the firm found within the clinical trials that there was inadequate test sensitivity with clinical saliva samples, along with challenges associated with patient recruitment and enrollment in the study “as local prevalence of the virus has diminished significantly.”

As a result, the company has indicated that it will be refocusing its resources on other rapid test and further research of its gold nanorod technology.

Sona Nanotech last traded at $1.02 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Uranium Is Back On America’s Radar | Corey Dias –  Anfield Energy

The Russell Will Lead the Next Market Crash!? | John Feneck

The Global Conflict Has Already Started | Bryan Cunningham

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

This Week In China: Easing COVID Policies, Boosting Property Market, Visiting Saudi Oil

As Last Week Tonight host John Oliver would say: “it has been a busy week.”...

Friday, December 9, 2022, 10:11:29 AM

Novavax Announces Purchase Agreement With European Commission For Up To 200 Million COVID-19 Vaccine Doses

Novavax, Inc. (Nasdaq: NVAX) announced today that it has reached an agreement with the European...

Wednesday, August 4, 2021, 10:27:00 AM

Mask Mandates Return as Rate of Hospitalization Increases in the US

Morris Brown College, a private Atlanta institution, has reissued a face mask mandate for its...

Wednesday, August 23, 2023, 02:09:00 PM

Market Movers: Sona Nanotech Moves On COVID-19 Antigen Test Validation

Sona Nanotech (CSE: SONA) is one of the largest movers and shakers of the last...

Monday, July 6, 2020, 02:24:37 PM

Sona Nanotech: Health Canada Evaluation Results Did Not Match Prior Analytical And Clinical Study Data

Sona Nanotech (CSE: SONA) this morning elaborated on its decision to withdraw its antigen test...

Monday, November 30, 2020, 09:16:04 AM